Clients

Galectin Therapeutics Inc.

Company Snapshot: Galectin Therapeutics Inc.

GALT
Last Change Volume High Low

Company Overview

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.

Featured Documents

Client News

  1. Jun 21 2017 Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
  2. Jun 13 2017 Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
  3. Jun 6 2017 Autoimmune Disease Patent Granted to Galectin Therapeutics
  4. May 15 2017 Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update